Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,566 shares of the biopharmaceutical company's stock after selling 7,260 shares during the quarter. Hantz Financial Services Inc.'s holdings in Gilead Sciences were worth $5,872,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Avior Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after acquiring an additional 108 shares during the last quarter. Southland Equity Partners LLC lifted its stake in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after purchasing an additional 110 shares during the last quarter. Concord Asset Management LLC VA boosted its holdings in shares of Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock worth $256,000 after purchasing an additional 111 shares in the last quarter. Berkshire Bank raised its holdings in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 111 shares in the last quarter. Finally, TFB Advisors LLC lifted its position in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after buying an additional 116 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on GILD shares. The Goldman Sachs Group raised their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Wolfe Research initiated coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an "outperform" rating and a $110.00 price target for the company. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Finally, Piper Sandler raised their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $98.39.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company's stock, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.16% of the company's stock.

Gilead Sciences Stock Up 0.6 %

Shares of GILD stock traded up $0.57 during trading hours on Thursday, reaching $96.16. 1,117,467 shares of the company's stock were exchanged, compared to its average volume of 6,496,817. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The stock's 50 day moving average is $92.14 and its 200-day moving average is $85.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $119.84 billion, a price-to-earnings ratio of 1,068.76, a P/E/G ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company's revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.29 earnings per share. Analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.